期刊文献+

国外药品效益风险评价研究进展 被引量:4

Overview of Drug Benefit-Risk Assessment Research Progress
下载PDF
导出
摘要 药品的效益风险评价是保证药品安全性的重要手段,因此建立科学、综合、统一的评价方法和框架尤为重要。本文从监管机构、行业组织以及企业3个角度,分别阐述国外药品效益风险评价的热点问题与研究进展。同时结合我国研究现状,对国内药品效益风险评价提出建议。 Benefit-risk assessment is an important means of ensuring drug safety, so it is particularly important to establish scientific, comprehensive and unified evaluation method and framework. In order to understand the foreign research situation of drug benefit-risk assessment, this article describes the hot topics and research progress among agencies, industry organizations, as well as enterprise, and further research areas. Moreover, based on the present situation of our drugs benefit-risk assessment. regulatory summerises the challenges and prospects of current country, the article provides reference for domestic
出处 《中国药物警戒》 2013年第8期473-477,共5页 Chinese Journal of Pharmacovigilance
关键词 药品 效益 风险 评价 drugs benefit risk assessment
  • 相关文献

参考文献15

  • 1Dr Theresa Mullin. US regulator's perspective on risk-benefit considerations[EB/OL]. ( 2010-6-1 ) .http:llcirsci.orglsitesldefaultl files/1020B% 20CMR% 20International% 20Institute% 20June% 202010%20Workshop.pdf.
  • 2Nikolaos Zafiropoulos, Lawrence Phillips, Francesco Pignatti. Evaluating benefit-risk: An Agency perspective[J]. Regulatory Rapporteur.2012, 6 (9):5-8.
  • 3EMA.'Benefit-risk methodology project: Work package 1 report: Description of the current practice of benefit-risk assessment for centralised procedure products in the European Union regulatory network'(EMA/227124/2011) [EB/OL].(2011-5-25). http://www. ema.europa.eu/docs/en_GB/document_library/Report/2011/07/ WC500109478.pdf.
  • 4EMA.'Benefit-risk methodology project: Work package 2 report: Applicability of current tools and processes for regulatory benefit- risk assessment' (EMA/549682/2010). [EB/OL].(2010-8-31).http:// www.ema.europa.eu/docs/en_GB/document_library/Report/2010/ 10/WC500097750.pdf.
  • 5EMA.'Benefit-risk methodology project: Work package 3 report: Field tests'(EMA/718294/2011) [EB/OL].( 2011-8-31 ). http://www. ema.europa.eu/docs/en_GB/document_library/Report/2011/09/ WC500112088.pdf.
  • 6EMA. 'Benefit-risk methodology project: Work package 4 report: Benefit-risk tools and processes'(EMA/29740512012)[EB/OL]. (2012-05-09).http://www.ema.europa.eu/docs/en_GB/document_ library/Report12012/O3/WC500123819.pdf.
  • 7Stuart Walker, Neil McAuslane, Lawrence Liberti. Developing a common benefit-risk assessment methodology foe medicines-a progress report. [EB/OL]. ( 2011 - 12 - 1 ), http ://cirsci.org/sy stern/files/ privatelSRA_Dec%202011 Dcveloping_.Walker McAuslanc_Liberfi% 5B 1%SD.pdf.
  • 8Dr Petra D.?rr. Improving the Benefit- Risk Assessment of Medicines: A "Consortium" Initiative[EB/OL].(2010-6-1 ). http://cirsci.org/sites/ default/flles/1020B% 20CMR% 20International% 20Institute% 20June% 202010%20Workshop.pdf.
  • 9By Lawrence Liberti, Stuart R. Walker, Progress on the Development of a Benefit/Risk Framework for Evaluating Medicines [EB/OL]. [2010-3] .http://cirsci.org/system/files/private/2010FocusLiberti_0.pdf.
  • 10PM Coplan, RA Noel, BS Levitan, et al.Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit-Risk Balance of Medicines [EB/OL]. ( 2010-12-1 ).http://cmpi.org/uploads/File/benefit-dsk-journal- article.pdf.

同被引文献46

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部